Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Inclusion Criteria: * Patients with symptomatic multiple myeloma (MM), with at least one prior line of chemotherapy or newly diagnosed without any prior therapy. * Zebroid ≤ 2, unless solely due to symptoms of MM-related bone disease (Appendix 4). * Patients must be at least 18 years of age and not older than 75 years of age at the time of registration. * Patient must not have had a prior auto- or allotransplant. * Patient must have signed an IRB-approved informed consent and understand the investigational nature of the study. * Patients must have adequate pulmonary function studies ≥ 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) ≥ 50% of predicted, within 60 days prior to enrollment. Patients unable to complete pulmonary function tests because of myeloma-related chest pain, must have a high resolution CT scan of the chest and must also have acceptable arterial blood gases defined as P02 greater than 70. * Ejection fraction by ECHO or MUGA must be ≥ 40% and must be performed within 60 days prior to enrollment, unless the patient has received chemotherapy within that period of time (dexamethasone and thalidomide excluded), in which case the LVEF must be repeated. * Patients must not have prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has not received treatment for one year prior to enrollment. Other cancers will only be acceptable if…